Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Amarin Corporation plc has announced that its president and CEO, John F. Thero, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, from 2:00 to 2:40 p.m. Eastern Time. A live audio webcast will be accessible at amarincorp.com for 30 days following the event.

Amarin focuses on cardiovascular health with its lead product, VASCEPA (icosapent ethyl), currently prescribed in the U.S., Canada, Lebanon, and the UAE. The company is pursuing further regulatory approvals in China, Europe, and the Middle East.

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 from 2:00 - 2:40 p.m. Eastern Time.

A live audio webcast of the presentation will be available at: http://www.amarincorp.com and will be accessible at the same link for 30 days.

About Amarin

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more information about Amarin, visit www.amarincorp.com.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information
Investor Inquiries:
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
IR@amarincorp.com (investor inquiries)

Solebury Trout
AmarinIR@troutgroup.com

Media Inquiries:
Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
PR@amarincorp.com (media inquiries)

FAQ

When will Amarin present at the J.P. Morgan Healthcare Conference?

Amarin's presentation at the J.P. Morgan Healthcare Conference is scheduled for January 12, 2021, from 2:00 to 2:40 p.m. Eastern Time.

Where can I watch the Amarin presentation live?

The live audio webcast of Amarin's presentation can be accessed at amarincorp.com.

What is VASCEPA and where is it available?

VASCEPA (icosapent ethyl) is Amarin's lead product, available by prescription in the U.S., Canada, Lebanon, and the UAE.

Is VASCEPA approved in other countries?

VASCEPA is not yet approved for sale in countries outside the U.S., Canada, Lebanon, and the UAE, but Amarin is seeking regulatory approvals in China, Europe, and the Middle East.